Innovent Tech company information, Employees & Contact Information

China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study Reuters

Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss study Fierce Pharma

Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assets Fierce Biotech

China's Innovent signs cancer therapy deal with Japan's Takeda Yahoo

Takeda Inks Deal With China’s Innovent to Develop Cancer Drugs Bloomberg

China's Innovent signs cancer therapy deal with Japan's Takeda Reuters

Innovent Announces 2025 Interim Results and Business Updates PR Newswire

Innovent raises HKD$4.3B to advance R&D pipeline, global expansion BioWorld MedTech

Innovent Biologics has announced $1 Billion ADC Oncology Licensing Agreement with Roche Oncodaily

Neutral On Innovent Biologics: Hard To Justify Its Premium (OTCMKTS:IVBXF) Seeking Alpha

Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management PR Newswire

Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout Fierce Pharma

/C O R R E C T I O N -- Innovent Biologics/ Yahoo Finance

Innovent Wins China Nod For Obesity Drug Rivaling Novo, Lilly Bloomberg

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors Business Wire

Roche returns to Innovent Biologics with new $1B biobucks ADC drug deal Fierce Biotech

Innovent's weight-loss drug highlights China challenge for Novo, Lilly Reuters

With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs Fierce Pharma

Watch Innovent on Seizing 'DeepSeek Moment' for Biotech Bloomberg

Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress PR Newswire

China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion - WSJ The Wall Street Journal

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire

Innovent takes the dual payload glory | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms Yahoo Finance

Roche licenses Innovent antibody-drug conjugate Chemical & Engineering News

Takeda Bets up to $11.4B for Three Innovent ADCs BioSpace

ESMO: Innovent links cytokine fusion protein to responses in colorectal cancer Fierce Biotech

Innovent’s mazdutide superior to Trulicity in Phase III T2D trial Clinical Trials Arena

Innovent, awaiting Chinese regulators' verdict, posts another psoriasis win for IL-23 drug Fierce Biotech

Innovent wins China approval for obesity drug mazdutide The Pharma Letter

Innovent Is Said to Consider Licensing Partnership for Cancer Drug Bloomberg

Innovent braves bruising cytokine space, linking fusion protein to tumor responses in small study Fierce Biotech

Mankind Pharma and Innovent partner for sintilimab The Pharma Letter

Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug Fierce Biotech

Innovent ditches low-value stake sale after investor outcry thebambooworks.com

Innovent gets IND for oral GLP-1 agonist BioWorld MedTech

Looking east, Sanofi pens 'pioneering' cancer drug partnership with China's Innovent Fierce Biotech

Innovent's Tepezza rival one step closer to Chinese approval after phase 3 eye disease win Fierce Biotech

[Fact Check] China's Innovent to Relocate Closed US Lab to California 一财全球Yicai Global

Lilly's next-gen obesity drug brings Innovent a phase 3 win in diabetes Fierce Biotech

China's Innovent Biologics secures over $300 million investment from Sanofi Reuters

Lummus and InnoVent Renewables sign MoU for tire pyrolysis technology Tire Technology International Magazine

Eli Lilly, Innovent hit with FDA rejection for China-developed lung cancer drug after tough review Fierce Pharma

FDA sets an example through Eli Lilly, Innovent's PD-1, rocking the boat for future contenders: analyst Fierce Pharma

Innovent plucks Chinese rights to LG Chem's gout disease treatment in nearly $100M deal Fierce Biotech

Innovent Biologics Closes ADC-Focused Maryland Site, Lays Off Researchers BioSpace

Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug Fierce Pharma

Innovent's anti-VEGF drug matches Eylea in phase 2 eye disease trial Fierce Biotech

Watch Innovent Reports Strong Start for Obesity Drug Bloomberg

InnoVent Renewables Achieves Key Early Milestones Towards Growth Newswire.com

Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro? Fierce Biotech

NMPA clears drugs from Innovent/Hutchmed, Hengrui, Henlius, Luye BioWorld MedTech

150+ Patient Trial: Innovent's Enhanced VEGF/Ang2 Drug Aims to Beat Market Leader in Eye Disease Stock Titan

Innovent's Dual Cancer Innovation Platform Shows Breakthrough Results in Clinical Trials Stock Titan

World's First Dual GCG/GLP-1 Drug Shows 87.4% Success Rate: Innovent's Mazdutide Approved in China Stock Titan

'In the long-term interests': FDA oncology chief defends rejection of Lilly, Innovent cancer drug Fierce Pharma

50.6% Revenue Growth: Innovent's Portfolio Hits 16 Drugs as Biopharma Giant Sets RMB 20B Revenue Target by 2027 Stock Titan

Innovent Bio hopes for plus-sized profits from obesity drug thebambooworks.com

Innovent's phase 3 hits tee it up to challenge Amgen and Sanofi for Chinese PCSK9 market Fierce Biotech

It Looks Like The CEO Of Innovent Biologics, Inc. (HKG:1801) May Be Underpaid Compared To Peers simplywall.st

Innovent buys Chinese rights to Incyte drugs for $40M upfront Fierce Biotech

Watch Innovent Biologics CEO on Pharma Industry, Prices, Pipeline, Cancer Cure Bloomberg

Innovent gears up for PD-1 inhibitor launch in China PMLiVE

China’s Innovent to start US trials of anti-CD47 cancer drug PMLiVE

China's Innovent in $120M bispecifics partnership with EpimAb Fierce Pharma

Mankind Pharma inks pact with Innovent for immunotherapy drug in India Business Standard

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) ANTARA News

Innovent Raises US$100 Million Asian Scientist Magazine

Innovent & Lilly Announce US$456 Million Cancer Drug Deal Asian Scientist Magazine